



**Company Contact:**  
**Jie Du, Ph.D.**  
**President & CEO**  
**JDP THERAPEUTICS, INC.**  
**Tel: 215-661-8557**  
**Email: [jjedu@jdptherapeutics.com](mailto:jjedu@jdptherapeutics.com)**  
**[www.jdptherapeutics.com](http://www.jdptherapeutics.com)**

## **JDP Therapeutics Establishes Medical Advisory Board**

**LANSDALE, PENNSYLVANIA, August 18, 2011** – JDP Therapeutics Inc., a privately held clinical stage specialty pharmaceutical company, announced today the establishment of its Medical Advisory Board (MAB). JDP’s MAB is composed of three world renowned allergy experts: Robert Naclerio, M.D., William Berger, M.D., and Michael Blaiss, M.D.

“The recent formation of this Medical Advisory Board represents a defining moment in JDP’s evolution as a clinical development company for allergy therapies,” said JDP’s President and CEO, Jie Du, Ph.D., “The members of this Board are all highly esteemed, outstanding and distinguished Key Opinion Leaders within the allergy field, and we are grateful to have the opportunity to draw upon their collective expertise as we continue to enhance our clinical program on JDP’s lead candidates JDP-205 and JDP-207”.

Joining the JDP Medical Advisory Board are:

### **Robert M. Naclerio, M.D.**

Dr. Naclerio is the Section Chief of Otolaryngology at the University of Chicago. Dr. Robert Naclerio is internationally recognized for his landmark research in allergic and non-allergic rhinitis. Dr. Naclerio has presented more than 400 lectures in the United States and foreign countries. He also has published more than 280 clinical articles and 70 book chapters. In his clinical work, Dr. Naclerio specializes in the management of sinusitis in children and adults.

### **William E. Berger, M.D., M.B.A.**

Dr. Berger is a Clinical Professor at the College of Medicine, Division of Allergy and Immunology, at UC Irvine. He founded the Allergy and Asthma Associates of Southern California Medical Group where he practices both adult and pediatric allergy. Dr. Berger served as a member of the joint Task Force on Practice Parameters, Chairman of the Managed Care Committee of the American College of Allergy, Asthma and Immunology, and Chairman of the Mission Hospital Institutional Review board.

### **Michael Blaiss, M.D.**

Dr. Blaiss is Clinical Professor of Pediatrics and Medicine at the University of Tennessee Health Sciences Center in Memphis and in private practice in Memphis at Allergy and Asthma Care. He was named to the list of Best Doctors in America for 1999-2010. Dr. Blaiss is presently on the Board of Directors of the World Allergy Organization. He is a Past President of the American College of Allergy, Asthma, and Immunology and has served on the Board of Directors for the American Board of Allergy and Clinical Immunology.

**About JDP Therapeutics Inc.**

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email [info@jdptherapeutics.com](mailto:info@jdptherapeutics.com)

###

*Safe Harbor Statement Regarding Forward-looking Statements*

*The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.*